04684nam 2200613 450 991055513190332120170924203359.01-68367-340-91-68367-098-11-55581-741-6(CKB)3710000000376186(EBL)3563369(SSID)ssj0001518274(PQKBManifestationID)12621511(PQKBTitleCode)TC0001518274(PQKBWorkID)11509719(PQKB)10329051(MiAaPQ)EBC3563369(PPN)19286100X(EXLCZ)99371000000037618620150627h20152015 uy 0engur|n|---|||||txtccrAntibodies for infectious diseases /edited by James E. Crowe, Jr., Diana Boraschi and Rino RappuoliWashington, District of Columbia :ASM Press,2015.©20151 online resource (476 p.)Description based upon print version of record.1-55581-735-1 Includes bibliographical references and index.""Cover ""; ""Half Title ""; ""Title Page ""; ""Copyright ""; ""Contents ""; ""Contr ibutors ""; ""Preface ""; ""INTRODUCTION""; ""Chapter 1: History and Practice: Antibodies in Infectious Diseases""; ""HISTORICAL PERSPECTIVE""; ""INTRODUCTION TO ANTIBODIES""; ""METHODS AND PLATFORMS FOR GENERATING ANTIBODIES""; ""STRATEGIC CONSIDERATIONS IN DEVELOPING ANTIBODY-BASED THERAPIES FOR INFECTIOUS DISEASES""; ""EXAMPLES OF ANTIBODIES THAT ARE OR WERE IN DEVELOPMENT FOR INFECTIOUS DISEASES""; ""FUTURE PERSPECTIVES FOR ANTIBODY TREATMENTS IN INFECTIOUS DISEASES""; ""ACKNOWLEDGMENT""; ""CITATION""""REFERENCES""""GENERAL FEATURES OF IMMUNOGLOBULINS""; ""Chapter 2: Functions of Antibodies""; ""INTRODUCTION""; ""ANTIBODY FUNCTIONS INDEPENDENT OF EFFECTOR CELLS OR EFFECTOR MOLECULES""; ""INHIBITION OF LATER STEPS""; ""ANTIBODY FUNCTIONS DEPENDENT ON COMPLEMENT""; ""ANTIBODY FUNCTIONS DEPENDENT ON Fc-Fc RECEPTOR INTERACTIONS""; ""OTHER ANTIBODY FUNCTIONS""; ""CONCLUSIONS""; ""ACKNOWLEDGMENTS""; ""CITATION""; ""REFERENCES""; ""Chapter 3: Antibody Structure""; ""BASICS OF ANTIBODY STRUCTURE""; ""CDR H3: SIZE AND SUBTERFUGE""; ""HEAVY CHAIN DOMINATION AND FRAMEWORK CONTACTS""""DISULFIDES IN THE CDRs""""SELF-CARBOHYDRATE RECOGNITION: PENETRATING THE GLYCAN SHIELD""; ""UNUSUAL INDELS""; ""MECHANISMS OF ANTIBODY NEUTRALIZATION""; ""SUMMARY""; ""ACKNOWLEDGMENT""; ""CITATION""; ""REFERENCES""; ""Chapter 4: The Role of Complement in Antibody Therapy for Infectious Diseases""; ""INTRODUCTION""; ""COMPLEMENT ACTIVATION""; ""Ab-MEDIATED COMPLEMENT ACTIVATION""; ""EFFECTOR RESPONSES AND THEIR ROLE IN MAb TREATMENTS""; ""MANIPULATING Ab-MEDIATED COMPLEMENT RESPONSES""; ""COMPLEMENT EVASIVE PROPERTIES OF PATHOGENS""; ""CONCLUSIONS AND FUTURE PERSPECTIVE""""ACKNOWLEDGMENTS""""CITATION""; ""REFERENCES""; ""Chapter 5: Immunoglobulin E and Allergy: Antibodies in Immune Inflammation and Treatment""; ""IMMUNOLOGICAL MECHANISMS OF ALLERGIC DISEASES AND THE ROLE OF IgE ANTIBODIES""; ""IgE ANTIBODIES IN INFECTIOUS DISEASES""; ""ANTIBODIES IN THE TREATMENT OF ALLERGIES""; ""THE OPPOSITE SIDE OF THE COIN: HARNESSING THE ALLERGIC RESPONSE AGAINST CANCER AND THE EMERGENCE OF ANTIBODIES OF THE IgE CLASS FOR CANCER THERAPY""; ""CONCLUDING REMARKS AND FUTURE ROLES OF ANTIBODIES IN THERAPY""; ""ACKNOWLEDGMENTS""; ""CITATION""; ""REFERENCES""""ANTIBODY DISCOVERY APPROACHES""""Chapter 6: Phage and Yeast Display""; ""DISCOVERY OF THERAPEUTIC ANTIBODIES USING PHAGE DISPLAY TECHNOLOGY""; ""DISCOVERY OF THERAPEUTIC ANTIBODIES USING YEAST DISPLAY TECHNOLOGY""; ""CONCLUSIONS""; ""ACKNOWLEDGMENT""; ""CITATION""; ""REFERENCES""; ""Chapter 7: Efficient Methods To Isolate Human Monoclonal Antibodies from Memory B Cells and Plasma Cells""; ""MANY WAYS TO MAKE HUMAN MONOCLONAL ANTIBODIES""; ""EFFICIENT IMMORTALIZATION OF MEMORY B CELLS BY USING EBV AND CpG""""LONG-TERM CULTURE OF SINGLE PLASMA CELLS AND THEIR INTERROGATION USING MULTIPLE ASSAYS""ImmunoglobulinsCommunicable diseasesImmunological aspectsImmunoglobulins.Communicable diseasesImmunological aspects.616.0798Crowe James E. Jr.Boraschi D(Diana),Rappuoli RinoMiAaPQMiAaPQMiAaPQBOOK9910555131903321Antibodies for infectious diseases2815464UNINA